Clinical trials: Restless Legs Syndrome (RLS)
Restless Legs Syndrome
An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome
This is a multicenter, open-label trial to assess safety and tolerability of rotigotine (SPM 936) in subjects with idiopathic Restless Legs Syndrome (RLS), administered at an optimal dose for up to 1 year.
- Trial name
- NCT00263068
- Testing
- Rotigotine
- Where
- United States
- Volunteers
- 279 people
- Sponsor
- UCB Pharma
Restless Legs Syndrome
Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs
The proposed study is a Cross-sectional epidemiological study, performed in 330 primary care practices in Germany. The study will be conducted on a fixed day in November 2007.
- Trial name
- NCT00557258
- Where
- 251 sites in Germany
- Volunteers
- 14,956 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Restless Legs Syndrome
A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.
The objective of double blind phase in this trial is to compare the efficacy and safety at the fixed dose of 0.25 mg,0.5 mg and 0.75 mg pramipexole in RLS.
- Trial name
- NCT00390689
- Testing
- Pramipexole 0.125 mg tablet, Pramipexole 0.5 mg tablet
- Where
- 34 sites in Japan
- Volunteers
- 154 people
- Sponsor
- Boehringer Ingelheim
RLS
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe…
- Trial name
- RLS (NCT02633683)
- Testing
- HORIZANT 600 mg
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in…
- Trial name
- NCT00367822
- Testing
- Lisuride, Ropinirole
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Axxonis Pharma AG
Restless Legs Syndrome
A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS
The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (PLMS) arousl index and sleep efficiency in patients with RLS.
- Trial name
- NCT00627003
- Testing
- Cabergoline
- Volunteers
- 43 people
- Sponsor
- Pfizer
Restless Legs Syndrome
Simulated Driving Study in Restless Legs Syndrome
This study was a multi center, randomized, double blind, active and placebo controlled, parallel group study to assess simulated driving performance in XP13512 treated subjects with Restless Legs Syndrome (RLS).
- Trial name
- XP083 (NCT01332318)
- Testing
- XP13512, Diphenhydramine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance
The purpose of this study is to assess the efficacy and safety of pregabalin and pramipexole versus placebo in the treatment of restless legs syndrome and associated sleep disturbance.
- Trial name
- NCT00991276
- Testing
- pregabalin, pramipexole
- Where
- 41 sites in United States
- Volunteers
- 85 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Restless Legs Syndrome
Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)
The purpose of this study was to evaluate the efficacy and safety of different doses of pramipexole (Sifrol) on subjective and objective symptoms of idiopathic Restless Legs Syndrome (RLS) and also to determine the optimal dose…
- Trial name
- NCT00239486
- Testing
- Pramipexole
- Where
- Finland
- Volunteers
- 109 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
Study to determine the pharmacokinetics (PK) of pramipexole (PPX) after administration of a single dose orally (p.o.) in pediatric patients with the diagnosis of RLS
- Trial name
- NCT02231918
- Testing
- MIRAPEX® - low, MIRAPEX® - medium, MIRAPEX® - high
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00365352
- Testing
- XP13512 600MG, XP13512 1200MG
- Volunteers
- 325 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Rating Scale and Global Clinical…
- Trial name
- NCT00721279
- Testing
- Sifrol® (pramipexole dihydrochloride)
- Where
- 127 sites in Austria
- Volunteers
- 549 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00311363
- Testing
- GEn (XP13512)
- Volunteers
- 327 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
The primary objective of this study is to determine that pramipexole (Sifrol) 0.25 mg to 0.75 mg daily is not inferior to levodopa 100 mg to 300 mg (in combination with benserazide 25mg to 75mg = Madopar DR) daily in the…
- Trial name
- NCT00144209
- Testing
- pramipexole, levodopa in combination with benserazide
- Where
- 6 sites in Switzerland
- Volunteers
- 58 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks
- Trial name
- NCT00314860
- Testing
- ropinirole Extended Release (XR)
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 568 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
This double-blind study will evaluate the pharmacokinetics of a single dose of morphine or gabapentin derived from gabapentin enacarbil (GEn) after administration of morphine and GEn alone and in combination as well as the…
- Trial name
- NCT01476124
- Testing
- GEn 600 mg, Morphine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Long-term Study Of Ropinirole In Restless Legs Syndrome
This is an initial placebo-controlled study followed by open treatment evaluating the effectiveness and tolerability of ropinirole long-term in patients with moderate to severe Restless Legs Syndrome.
- Trial name
- NCT00329602
- Testing
- Ropinirole
- Where
- 39 sites in Australia, Czechia and 9 more
- Volunteers
- 404 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
A 12-week clinical research study to evaluate the tolerability, efficacy and safety of ropinirole compared to placebo(an inactive sugar pill) in the treatment of patients with RLS in the United States.
- Trial name
- NCT00225862
- Testing
- ropinirole
- Where
- 37 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome, End-Stage Renal Disease
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
This is a sleep laboratory study to evaluate the efficacy and safety of Rotigotine in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis.
- Trial name
- NCT01537042
- Testing
- Rotigotine
- Where
- 15 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- UCB BIOSCIENCES GmbH
Restless Legs Syndrome
Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation
This study evaluates Tonic Motor Activation (TOMAC) therapy in adults with restless legs syndrome and dopaminergic augmentation.
- Trial name
- CT-10 (NCT07397247)
- Testing
- Tonic Motor Activation (TOMAC) Device
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Noctrix Health, Inc.